07/16/2004 HALI11 00000066 181945

1	OIPE
	JUL 1 5 2004 8
13	TOARE LEVE

PTO/SB/30 (09-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

mation unless it displays a valid OMB control numbe

Office the Paperwork Neddelight Act of 1999, no persons are required to respond to a confedent of the interest among a capacity of the confedent of the interest among a capacity of the confedent of the interest among a capacity of the confedent of the interest among a capacity of the confedent of the interest among a capacity of the confedent of the interest among a capacity of the confedent of the interest among a capacity of the confedent of the interest among a capacity of the confedent of t						
Request	Application Number	09/735273				
For Continued Examination (RCE)	Filing Date_	December 11, 2000				
Transmittal	First Named Inventor	Edwin A. Clark				
rransmillai	First Named Inventor	Edwin A. Clark				
Address to: MS RCE	Art Unit	1634				
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Examiner Name	J. C. Switzer				
Additional, VA 22010-1400	Attorney Docket Number	WIBL-P01-534				

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June

8, 1995, or to any design application. 1. Submission required under 37 CFR 1.114 | Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked. Consider the arguments in the Appeal Brief or Reply Brief previously filed on ii. b. x Enclosed iii. X Information Disclosure Statement (IDS) Amendment/Reply Affidavit(s)/Declaration(s) 2. Miscellaneous Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required) The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. 3. Fees The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 18-1945 X RCE fee required under 37 CFR 1.17(e) Extension of time fee (37 CFR 1.136 and 1.17) Check in the amount of \$ enclosed Payment by credit card (Form PTO-2038 enclosed) SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED Registration No. (Attorney/Agent) 55,745 Xuqiong Wu Name (Print/Type) July 12, 2004

I hereby certify that this correspondence is b	eing deposited with the	U.S. Postal Service with sufficient postage as	First Class Mail, in
an envelope addressed to: MS RCE, Comm	issioner for Patents, P.0	D. Box 1450, Alexandria, VA 22313-1450, on	the date shown
below.			
	~	1 10.00.0	

7-12-04 Signature: Mausell, Yallsyker (Maura Gallagher)

770.00 DA



AMEN	Docket No. WIBL-P01-534							
Application No. 09/735273		Filing December		Examiner J. C. Switzer	Art Unit 1634			
Applicant(s): Clar	k et al.	<u> </u>						
Invention: METAS	STASIS GENE	S AND USES	THEREOF					
TO THE COMMISSIONER FOR PATENTS								
Transmitted here								
The fee has been	n calculated an							
	Claims	CLAIM Highest	S AS AMENI	DED				
	Remaining After Amendment	Number Previously Paid	Number Extra Claims Present	Rate				
Total Claims Independent	11	- 35 =	0	X	0			
Claims	6	- 13 =	0	х	0			
Multiple Depend	lent Claims (ch	eck if applicabl	e)					
Other fee (pleas	Other fee (please specify): Request for Continued Examination: \$770.00							
TOTAL ADDITI	ONAL FEE FO	OR THIS AME	NDMENT:		\$770.00			
x Large Entity				Small Entity				
No additiona	I fee is require	d for this amer	ndment.					
	ge Deposit Acc			n the amount of \$	770.00 .			
A check in th	ne amount of \$		to cover	the filing fee is enclo	osed.			
Payment by	credit card. Fo	orm PTO-2038	is attached.					
	is hereby auth I below. A dup			Deposit Account No	18-1945			
	ny overpaymer							
			n processing t	fees required under 3	7 CFR 1.16 and 1.17.			
			,	·				
Yugioro Wu	July 12, 2004							
	Xuqiong Wu Attorney Reg. No.: 55,745							
ROPES & GRAY LLP								
One International Place								
Boston, Massachusetts 02110-2624 (617) 951-7000								
					stage as First Class Mail, in			
below.		_		0, Alexandria, VA 22313-1				
Dated: 7-13	7-04	Signature: Ma	ura a.	Wellogher Maur	a A. Gallagher)			



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail, in an envelope addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the

date shown below.

Dated: 7-12-04 Signature: Maura A. Fallagher)

Docket No.: WIBL-P01-534

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Clark, et al.

Confirmation No.: 3583

Application No.: 09/735,273

Art Unit: 1634

Filed: December 11, 2000

Examiner: Juliet Caroline Switzer

For: METASTASIS GENES AND USES THEREOF

AMENDMENT TO ACCOMPANY REQUEST FOR CONTINUED EXAMINATION

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

This amendment is filed to accompany the Request for Continued Examination (RCE) being concurrently filed. A Notice of Appeal was received by the United States Patent and Trademark Office on May 10, 2004. Therefore, the deadline for filing a Brief on Appeal is July 10, 2004. However, since July 10, 2004 was a Saturday, pursuant to 37 C.F.R. § 1.7, a Brief on Appeal may be timely filed on Monday, July 12, 2004. In lieu of filing a Brief on Appeal, Applicants are filing an RCE.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.